The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia

Journal of Oncology Pharmacy Practice

Volumn 22, Issue 1, 2016, Pages 76-81

  Sims, Rosalyn P ^a  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

Author keywords

Pediatric acute lymphoblastic leukemia; Racial group; Vincristine metabolism

Indexed keywords

CYTOCHROME P450 3A5; VINCRISTINE; CYP3A PROTEIN, HUMAN; CYTOCHROME P450 3A;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; AFRICAN AMERICAN; ALLELE; ARTICLE; CAUCASIAN; CHILD; CHILDHOOD LEUKEMIA; COMPARATIVE STUDY; DRUG CLEARANCE; DRUG METABOLISM; FEMALE; GAIT DISORDER; GENE AMPLIFICATION; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; JAW PAIN; LEG PAIN; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; NEUROTOXICITY; OBSERVATIONAL STUDY; PARESTHESIA; PRE B LYMPHOCYTE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PTOSIS; RACE DIFFERENCE; SCHOOL CHILD; SENSORY NEUROPATHY; SIDE EFFECT; TENDON REFLEX; WEAKNESS; ANCESTRY GROUP; GENETIC VARIATION; GENETICS; INFANT; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CONTINENTAL POPULATION GROUPS; CYTOCHROME P-450 CYP3A; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; INFANT; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; VINCRISTINE;

EID: 84960870190     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155214553143     Document Type: Article

References (15)

1. Kadan-Lottick NS, Ness KK, Bhatia S, et al. Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia. JAMA 2003; 290: 2008-2014.
2. Pollock BH, DeBaun MR, Camitta BM, et al. Racial differences in the survival of childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. J Clin Oncol 2000; 18: 813-823.
3. Lange BJ, Bostrom BC, Cherlow JM, et al. Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 99: 825-833.
4. Dennison JB, Kulanthaivel P, Barbuch RJ, et al. Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos 2006; 34: 1317-1327.
5. Dennison JB, Jones DR, Renbarger JL, et al. Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J Pharmacol Exp Ther 2007; 321: 553-563.
6. Dennison JB, Mohutsky MA, Barbuch RJ, et al. Apparent high CYP3A5 expression is required for significant metabolism of vincristine by human crypopreserved hepatocytes. J Pharmacol Exp Ther 2008; 327: 248-257.
7. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-391.
8. Renbarger JL, McCammack KC, Rouse CE, et al. Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr Blood Cancer 2008; 50: 769-771.
9. Xie HG, Wood AJJ, Kim RB, et al. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004; 5: 243-272.
10. Children's Oncology Group protocol AALL0331 (revised 25 September 2006).
11. Lopes LF, Piccoli Fde S, Paixao VA, et al. Association of CYP3A4 genotype with detection of Vg/Jb trans-rearrangements in the peripheral blood leukocytes of pediatric cancer patients undergoing chemotherapy for ALL. Leuk Res 2004; 28: 1281-1286.
12. Egbelakin A, Ferguson MJ, MacGill EA, et al. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2011; 56: 361-367.
13. Moore AS, Norris R, Price G, et al. Vincristine pharma-codynamics and pharmacokinetics in children with cancer: a limited-sampling, population modelling approach. J Paediatr Child Health 2011; 47: 875-882.
14. Roy JN, Lajoie J, Zijenah LS, et al. CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab Dispos 2005; 33: 884-887.
15. Lee SJ and Goldstein JA. Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests. Pharmacogenomics 2005; 6: 357-371.